Novartis Stock Tanks Following Third Major Pipeline Setback
Novartis stock experiences a sharp decline following a Phase 3 failure for a dystrophy drug linked to its $12 billion Avidity acquisition.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Shares of Novartis have plummeted following the announcement of a significant setback in the company's drug development pipeline. According to reporting from BioSpace, a drug designed to treat dystrophy has failed to meet expectations during Phase 3 clinical trials. This specific setback is particularly impactful because the drug is tied to the acquisition of Avidity, a deal valued at $12 billion. The coverage provided by BioSpace emphasizes the financial stakes involved in the Avidity acquisition and the timing of the clinical failure.
By highlighting the $12 billion price tag associated with the acquisition, the report underscores the magnitude of the potential loss in value. The reporting focuses on the transition from the acquisition phase to the clinical trial phase, specifically noting that the drug hit a speedbump during the final stages of testing, which is typically the last hurdle before regulatory approval and commercialization. To understand why this event is trending, it is necessary to view it within the context of Novartis' broader recent performance. In the pharmaceutical industry, Phase 3 trials are critical as they involve large patient groups to prove efficacy and safety; a disappointment at this stage often leads to the abandonment of the drug candidate and significant write-downs of the assets acquired to develop such treatments.
Moving forward, observers will be monitoring the fallout from this Phase 3 disappointment and how it affects the integration of Avidity. Because coverage does not specify the exact nature of the dystrophy drug's failure or the specific metrics that disappointed researchers, further details on the trial data are expected. The market will likely look for official statements from Novartis regarding the future of the Avidity partnership and whether other candidates in the acquired pipeline remain viable despite this specific setback.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (85% supported) Updated 66d ago.
Quick answers
How much did Novartis pay for the Avidity acquisition?
The acquisition was valued at $12 billion.
At what stage of development did the dystrophy drug fail?
The drug hit a speedbump during Phase 3 trials.
Is this the first setback for Novartis' pipeline?
No, BioSpace reports this is the third major pipeline setback for the company.
Coverage (1)
Topics
Related trends
Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
A former Eli Lilly sales representative has filed a retaliation lawsuit alleging she was fired for objecting to Mounjaro marketing.
Pelacarsen, a promising drug for an inherited heart risk, flops, stunning doctors
Medical experts are stunned after the promising cholesterol drug pelacarsen unexpectedly fails a key study, leading to its abandonment.
Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
Novartis reports cases of tumors in children following treatment with its spinal muscular atrophy gene therapy, Zolgensma.
Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
Revolution Medicines' pancreatic cancer drug Rasonque achieves an eye-popping commercial debut, shattering analyst estimates.
Novo Nordisk Lifts Guidance as Rollout of Wegovy Weight-Loss Pill Continues
Novo Nordisk raises its 2026 outlook and shares surge as the Wegovy weight-loss pill rollout accelerates.
Pfizer hikes full-year outlook as newer products grow, taps company veteran as new CFO
Pfizer has increased its 2026 full-year guidance following strong third-quarter results driven by growth in cancer and migraine medications.